In mitosis, for each daughter cell to inherit an accurate copy of the genome from the mother cell, sister chromatids in the mother cell must attach to microtubules emanating from opposite poles of the mitotic spindle, a process known as bi-orientation. A surveillance mechanism, termed the spindle assembly checkpoint (SAC), monitors the microtubule attachment process and can temporarily halt the separation of sister chromatids and the completion of mitosis until bi-orientation is complete 1 . SAC failure results in abnormal chromosome numbers, termed aneuploidy, in the daughter cells, a hallmark of many tumours. The HORMA-domaincontaining protein mitotic arrest deficient 2 (MAD2) is a subunit of the SAC effector mitotic checkpoint complex (MCC). Structural conversion from the open to the closed conformation of MAD2 is required for MAD2 to be incorporated into the MCC 1 . In vitro, MAD2 conversion and MCC assembly take several hours 2-4 , but in cells the SAC response is established in a few minutes [5] [6] [7] . Here, to address this discrepancy, we reconstituted a near-complete SAC signalling system with purified components and monitored assembly of the MCC in real time. A marked acceleration in MAD2 conversion and MCC assembly was observed when monopolar spindle 1 (MPS1) kinase phosphorylated the MAD1-MAD2 complex, triggering it to act as the template for MAD2 conversion and therefore contributing to the establishment of a physical platform for MCC assembly. Thus, catalytic activation of the SAC depends on regulated protein-protein interactions that accelerate the spontaneous but rate-limiting conversion of MAD2 required for MCC assembly.
In mitosis, for each daughter cell to inherit an accurate copy of the genome from the mother cell, sister chromatids in the mother cell must attach to microtubules emanating from opposite poles of the mitotic spindle, a process known as bi-orientation. A surveillance mechanism, termed the spindle assembly checkpoint (SAC), monitors the microtubule attachment process and can temporarily halt the separation of sister chromatids and the completion of mitosis until bi-orientation is complete 1 . SAC failure results in abnormal chromosome numbers, termed aneuploidy, in the daughter cells, a hallmark of many tumours. The HORMA-domaincontaining protein mitotic arrest deficient 2 (MAD2) is a subunit of the SAC effector mitotic checkpoint complex (MCC). Structural conversion from the open to the closed conformation of MAD2 is required for MAD2 to be incorporated into the MCC 1 . In vitro, MAD2 conversion and MCC assembly take several hours [2] [3] [4] , but in cells the SAC response is established in a few minutes [5] [6] [7] . Here, to address this discrepancy, we reconstituted a near-complete SAC signalling system with purified components and monitored assembly of the MCC in real time. A marked acceleration in MAD2 conversion and MCC assembly was observed when monopolar spindle 1 (MPS1) kinase phosphorylated the MAD1-MAD2 complex, triggering it to act as the template for MAD2 conversion and therefore contributing to the establishment of a physical platform for MCC assembly. Thus, catalytic activation of the SAC depends on regulated protein-protein interactions that accelerate the spontaneous but rate-limiting conversion of MAD2 required for MCC assembly.
The SAC temporarily targets the activity of the E3 ubiquitin ligase anaphase promoting complex/cyclosome (APC/C), which is required for mitotic exit (Fig. 1a) . Two SAC proteins, MAD2 and BUBR1 (the latter of which forms a constitutive complex with BUB3), interact directly with cell-division cycle protein 20 (CDC20), an APC/C co-activator. The resulting quaternary complex, comprising MAD2, BUBR1-BUB3 and CDC20, represents the core of the mitotic checkpoint complex (MCC core ), which is the SAC effector [8] [9] [10] [11] ( Fig. 1a and Extended Data Fig. 1a, b) . MCC core binds APC/C, which is already bound to a second CDC20 molecule, inhibiting its activity [12] [13] [14] . Thus, CDC20, an APC/C co-activator when devoid of SAC proteins, becomes an APC/C inhibitor when bound to SAC proteins in the MCC.
MAD2 binds the MAD2-interacting motif (MIM) of CDC20. This promotes a topological remodelling of MAD2 in which its 'safety belt' , a structurally mobile element comprising around the last 45 residues of MAD2, changes from an open (O-MAD2) to a closed conformation (C-MAD2) 15, 16 (Extended Data Fig. 1c ). Direct measurements have indicated that O-MAD2 binds to the CDC20 MIM with a dissociation constant (K d ) of approximately 10 −7 M (refs 15, 16) . However, when measured in vitro, the reaction appeared to have a remarkably small on-rate constant [2] [3] [4] , probably because structural remodelling of MAD2 requires a large activation energy. Thus, binding of MAD2 to CDC20 may be rate-limiting for SAC activation; because SAC reactivation takes only minutes in cells [5] [6] [7] , this binding reaction is likely to be catalysed.
To identify this catalyst, we tagged recombinant human O-MAD2, CDC20, and BUBR1 with fluorophores, creating Förster resonance energy transfer (FRET) sensors for MCC assembly. MCC sensor 1 (MCC S1 ) monitors the binding of cyan fluorescent protein (CFP)-tagged CDC20 (CFP-CDC20) and O-MAD2-TAMRA ( We measured the FRET-acceptor fluorescence of MCC S1 at different concentrations of O-MAD2 after a 15-h pre-incubation, which allowed the system to reach equilibrium (Fig. 1c, red curve) . The dissociation constant of the CDC20-C-MAD2 interaction (K d = 150 nM) was similar to that previously measured using CDC20 peptides that contain the MIM motif 3, 15, 16 . When we titrated O-MAD2 in the presence of dark (that is, non-fluorescently labelled) BUBR1, 3 nM O-MAD2 was sufficient to obtain half-maximal saturation of MCC S1 (the apparent K d (K d,app ); defined in Supplementary Information Section A), indicating a strongly augmented (by approximately 50-fold) binding affinity (Fig. 1c, blue curve) .
There was no FRET signal from MCC S2 in the absence of CDC20, indicating that CDC20 is necessary for the high-affinity binding of BUBR1 and O-MAD2 (Extended Data Fig. 2d ). As for MCC S1 , the K d,app for the binding of O-MAD2 to BUBR1 in the presence of CDC20 was 3 nM (Fig. 1c, green curve) , indicating that the chosen position of the fluorophores does not interfere with MCC assembly. Co-elution of the four subunits of MCC S1 from a size-exclusion chromatography column further supports this conclusion (Extended Data Fig. 2f) .
Removal of BUB3 did not affect the stability of MCC (Extended Data  Fig. 2g ). BUBR1 binds CDC20 in the MCC core through its first KEN-box (KEN1) motif 12 (Extended Data Fig. 1a) . These studies at equilibrium support two notable conclusions: (1) MCC core assembly is high-affinity, so BUBR1, CDC20, and O-MAD2, whose cellular concentrations are at least ten times higher than the K d,app values that we measured (Supplementary Information Section B), are expected to associate spontaneously; and (2) interactions that engage two MCC subunits are strongly augmented upon addition of the third subunit (for example, BUBR1 augments the CDC20-MAD2 interaction).
We used MCC S2 to measure MCC assembly by FRET in real time. The time-dependence of the FRET signal could be fitted with a single exponential function to yield an apparent reaction rate (k obs ) that increased linearly with the concentration of MAD2 (Extended Data  Fig. 4a, b) , indicative of pseudo-first-order kinetics. At a nearphysiological concentration of MCC components (100 nM), MCC assembly, as measured with MCC S2 , was very slow, with a half-life (t 1/2 ) of approximately 220 min (or 13,200 s; Fig. 2a ). MCC S1 displayed precisely the same slow rates as MCC S2 (Extended Data Fig. 4d , red curve) and omission of BUBR1 did not change the rate of activation of MCC S1 (Extended Data Fig. 4d , red and blue curves). Instead, when O-MAD2-TAMRA and CDC20 were pre-incubated, and CFP-BUBR1 was added to pre-formed CDC20-C-MAD2-TAMRA, MCC formation was practically instantaneous (Fig. 2a) . Thus, reorganization of the MAD2 safety belt upon binding of O-MAD2-TAMRA and CFP-CDC20 may limit the rate of MCC core assembly 3 and, as such, it is the likely target of the catalytic apparatus of the SAC (Fig. 1a) .
The MAD1-C-MAD2 complex forms the kinetochore receptor of O-MAD2 and has been proposed to accelerate its conversion, which is required for CDC20 to bind via a template-directed mechanism 17, 18 (the MAD2 template model, see Supplementary Information Section C). Previous studies, however, detected only modest effects of MAD1-C-MAD2 on MCC assembly in vitro, which were clearly insufficient to account for the rapid accumulation of the MCC in living cells 3, 4, 17 . MAD1-C-MAD2 might therefore require an activator. In looking for this activator, we focused on the protein kinases BUB1-BUB3 and MPS1, owing to their role in the regulation of MAD1-C-MAD2 (ref. 1).
We pre-incubated recombinant MAD1-C-MAD2, BUB1-BUB3, and MPS1 at a concentration of 1 μ M for 30 min at 30 °C with ATP and Mg 2+ , before diluting them at different concentrations into solutions containing MCC S2 (Fig. 2b ). Even at low-nanomolar concentrations, pre-incubated MAD1-C-MAD2, BUB1-BUB3 and MPS1 strongly increased the rate of MCC assembly (Fig. 2b) . The initial velocity of MCC formation increased linearly as a function of catalyst concentration (Extended Data Fig. 4e ). At concentrations (25-50 nM) comparable to those reported to exist in cells, pre-incubated MAD1-C-MAD2, BUB1-BUB3 and MPS1 caused the MCC-binding reaction to equilibrate in minutes (t 1/2 = 165 and 82 s for 25 and 50 nM, respectively; Fig. 2b ), in line with signalling dynamics in vivo 5, 6 . At equivalent concentrations of MCC subunits and catalytic activators, the behaviour of MCC S1 was essentially indistinguishable from that of MCC S2 (Extended Data Fig. 4f ). Thus, our in vitro assay captures a crucial catalytic activation step of the SAC. To identify the factors necessary for rapid accumulation of the MCC, we omitted individual components from the pre-incubation step (catalyst concentrations in these experiments are discussed in Supplementary Information Section D). Removing MAD1-C-MAD2 prevented any acceleration of MCC formation (Fig. 3a) . Removing MPS1 (Fig. 3b) or ATP (Fig. 3c ) resulted in a strong reduction in the rate of MCC assembly. Removing BUB1-BUB3 still had a large effect but it was less substantial (Extended Data  Fig. 5a ).
Asymmetrical dimerization of O-MAD2 and C-MAD2 has previously been identified as part of the mechanism of MAD2 activation in the SAC 3, 17, 18 . We investigated whether mutations to MAD2 in the MAD1-C-MAD2 complex (the mutation of residues 133 and 141 to alanine), which prevent dimerization with O-MAD2 (refs 18,19) , would ablate the catalytic role of MAD1-C-MAD2. Indeed, MAD1-C-MAD2 R133A-F141A was inert, confirming that MAD2 dimerization is a crucial component of the catalytic mechanism (Fig. 3d) . N-terminal truncations of MAD1 (Extended Data Figs 1d, 2a) showed that residues 1-419 of MAD1 are dispensable for catalysis, whereas deletions affecting residues 420-485 decreased the catalytic function of MAD1-C-MAD2 (Extended Data Fig. 5b ).
MPS1 and BUB1 are protein kinases. We studied the relevance of kinase activity on the catalytic reaction with the small-molecule kinase inhibitors Reversine and BAY-320, which target MPS1 and BUB1, respectively 20, 21 (Extended Data Fig. 6a ). Addition of Reversine during pre-incubation had substantial negative consequences for the catalytic activation of MCC assembly, but its addition at the end of preincubation was fully compatible with catalysis. Thus, MPS1 activity is required only during pre-incubation (Fig. 4a) . Much milder effects were observed with BAY-320, suggesting that the kinase activity of BUB1 makes a relatively modest contribution to the catalytic activation of MCC (Extended Data Fig. 6b ).
We dissected the requirements for kinase activity by performing two separate pre-incubation reactions (with ATP): one with MPS1 and MAD1-C-MAD2 and the other with BUB1-BUB3. Catalysis was fully reconstituted when the two pre-incubation reactions were added to MCC S2 and CDC20 (Extended Data Fig. 6c ). Addition of Reversine to MPS1 and MAD1-C-MAD2 during pre-incubation strongly reduced the rate of MCC assembly (Extended Data Fig. 6d ), suggesting that MPS1 phosphorylates and activates MAD1-C-MAD2.
Using mass spectrometry, we identified several phosphorylation sites on the MAD1-MAD2 complex after in vitro phosphorylation with MPS1 (Extended Data Fig. 7a ). On the basis of sequence conservation, previous phosphoproteomic analyses (as summarized in the PHOSIDA (http://141.61.102.18/phosida/index.aspx) and Phosphosite Plus (http://www.phosphosite.org/homeAction.action) websites) and previous functional analyses, we prioritized four MPS1 phosphorylation sites located in two distinct regions: Ser428 of MAD1 (in the coiled-coil region of MAD1, upstream of the MIM), and Ser699, Ser713 and Thr716 (in the RWD domain) 15, 16, 22 (Extended Data Figs 1d and 7a). An alanine point mutation in Ser428 (S428A) had no effect on the catalytic activity of MAD1-C-MAD2 (Fig. 4b ). Conversely, a triple-alanine mutant of Ser699, Ser713 and Thr716 (S699A/S713A/ T716A, hereafter MAD1 RWD-A ) abrogated the catalytic role of MAD1 in MCC assembly. The residual response of MAD1 RWD-A was ascribed to BUB1, because when that was omitted, catalysis was completely abrogated. Our attempts to generate phospho-mimetic mutants of MAD1-C-MAD2 were frustrated by instability of the protein products (A.C.F. and A.M., unpublished data).
Removal of MAD1-C-MAD2 from the kinetochores following microtubule attachment is required to suppress SAC signalling. A chimeric fusion protein of wild-type MAD1 (MAD1 WT ) and MIS12 (which stably binds kinetochores) prevents MAD1 release and arrests mitosis at metaphase 23 . When expressed in HeLa cells, the MIS12-MAD1
WT chimaera created a durable checkpoint arrest in mitosis, which was suppressed by the inhibition of MPS1 with Reversine ( These observations suggest that MAD1-C-MAD2 and BUB1-BUB3 may both act as physical constituents of the catalyst of MCC assembly, in line with evidence that these proteins might interact physically (Supplementary Information Section E). To assess this theory, we used MCC S1 to measure the influence of BUB1-BUB3 on the binding of CDC20 and MAD2. When BUB1-BUB3 was omitted, a strong reduction in the formation of the CDC20-C-MAD2 complex was observed (Extended Data Fig. 8b ). This effect did not involve BUBR1-BUB3 (which binds directly to BUB1-BUB3) 24 , because omission of BUBR1-BUB3 did not influence the rate of FRET accumulation from MCC S1 (Extended Data Fig. 8b ). We next investigated whether BUB1 exercises its functions through CDC20. When using a BUB1 construct with mutations in the CDC20-binding motif (the KEN1-ABBA motif [25] [26] [27] ), we observed that the rate of assembly of CDC20-C-MAD2 was reduced to levels similar to those observed after removal of BUB1-BUB3 (Extended Data Fig. 8c) . Thus, the contribution of BUB1 to MCC assembly appears to require an interaction with CDC20, and we surmise that the kinase activity of BUB1 mildly stimulates this interaction.
MAD1 and BUB1 have previously been shown to interact [28] [29] [30] . We therefore investigated whether human MAD1-C-MAD2 and BUB1 form a complex by performing pull-down experiments in which MAD1 tagged with maltose-binding protein (MBP) and bound to C-MAD2 (MBP-MAD1-C-MAD2) was immobilized on amylose beads (Extended Data Fig. 8d ). We observed binding of BUB1-BUB3 to MBP-MAD1-C-MAD2 only in the presence of MPS1 kinase activity, suggesting that MPS1 triggers the interaction, as in Saccharomyces cerevisiae 28 . The interaction between MAD1-C-MAD2 and BUB1-BUB3 is transient and low affinity, as the proteins did not co-elute from a size-exclusion chromatography column (A.C.F., M.T., C.B. and A.M., unpublished results).
Our data indicate that BUB1-BUB3 and MAD1-C-MAD2 (the latter after appropriate modification by MPS1) accelerate the conversion of O-MAD2 to C-MAD2 that is required to bind CDC20. We propose that MPS1, MAD1-C-MAD2, and BUB1-BUB3 act strictly catalytically; that is, they do not effect changes in the free energy of association of the MCC subunits. To test this idea, we investigated whether the K d of MCC S2 (Fig. 1c ) changed when measured in the presence of catalysts (at 25 nM) at equilibrium. In agreement with our hypothesis, the presence of catalysts did not change the apparent binding affinity of MCC ; Fig. 5a ). Here, we have shown that the conversion of O-MAD2 to C-MAD2, which is required for binding CDC20, is the only rate-limiting step in the assembly of the MCC. MAD2 is not a catalyst for the interaction of BUBR1 and CDC20, as has been proposed 4, 31 ; rather, it binds BUBR1 and CDC20 in a stable ternary complex that assembles spontaneously at the cellular concentration of SAC proteins. One implication of this biochemical association is that the disassembly of the MCC requires energy. Several energy-dependent mechanisms of MCC disassembly have been described previously and are shown to operate continuously to disassemble MCC, even when the rate of MCC assembly is at its maximum 32 .
We have identified a phosphorylated form of MAD1-C-MAD2 as the crucial catalyst for the accumulation of CDC20-C-MAD2. Omission of MPS1 and usage of a truncated and partly inactive MAD1 construct probably explain why previous studies observed only modest catalytic activation of MAD2 in vitro 3 (see Supplementary Information Section F). Our results also indicate that dimerization of O-MAD2 with MAD1-C-MAD2, which was previously shown to be required for SAC signalling 17, 33 , is essential for catalysis. Two predictions made regarding the MAD2 template model-that MAD1-C-MAD2 is a catalyst and that O-MAD2-C-MAD2 dimerization is required for catalysis 17 -are therefore confirmed here (Fig. 5b, c) .
Kinetochores are likely to be required for a robust SAC response, particularly as they increase the local concentration of catalysts, probably favouring their post-translational modification and physical interaction. The role of kinetochores in SAC signalling may be particularly important under stringent conditions, such as when there is only one or a few unattached kinetochores in a cell 34 , a point at which the number of MCCs declines and the rate of degradation of APC/C substrates increases considerably 5, 35 . The tools we described here may aid the study of this unresolved issue.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
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No statistical methods were used to predetermine sample size. The experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment. Production of recombinant proteins. All recombinant proteins used in this study were of human origin. MAD2 was expressed and purified essential as described previously 18 . All proteins used in this study, except BUBR1 (residues 1-571), were full length. To generate fluorescent BUBR1 and CDC20, we introduced a Histagged N-terminal mTurquoise2 (ref. 36) . Expression of all other protein constructs and mutants was performed in Sf9 (CDC20 and BUB1-BUB3) or TnaO38 insect cells (all other proteins). After infection with virus (at multiplicity of infection 1:50), cultures were grown at 27 °C, collected after 3 days and pellets stored at − 20 °C. MAD1-C-MAD2 and BUBR1-BUB3 were cultured by mixing individual viruses, each harbouring individual genes. MPS1 was expressed in the presence of 2 μ M Reversine.
Generally, cells were lysed in buffer A (25 mM HEPES (pH 7.5), 300 mM NaCl, 10% glycerol, 2 mM TCEP, 1 mM PMSF). MAD1-C-MAD2 and CDC20 were purified in buffer A with 1,000 and 500 mM NaCl, respectively. Soluble lysate was passed over a 5-ml Ni-NTA column and, after washing with 20 column volumes buffer A, the proteins were eluted by adding 300 mM imidazole to buffer A. Proteins was subsequently gel-filtered on a Superdex S200 16/60 column equilibrated against buffer B (10 mM HEPES (pH 7.5), 150 mM NaCl, 5% glycerol, 2 mM TCEP). All buffers used in the purification of MPS1 were supplemented with 0.2% Triton X-100. Fractions containing purified proteins were concentrated, flash-frozen and stored at − 80 °C until use. TAMRA labelling of O-MAD2. Purified MAD2 was C-terminally labelled using the sortase A transpeptidase enzyme from Staphylococcus aureus, which catalyses the cleavage of a short five-amino-acid recognition sequence (LPETG) with the concomitant formation of an amide linkage between an oligoglycine peptide and the target protein 37 . To that end, we mixed 10-50 μ M MAD2-LPETG with 150 μ M sortase A and 0.5-1 mM of a TAMRA-conjugated peptide (Gly-Gly-Gly-GlyLys-TAMRA; StorkBio). The reactants were mixed in 50 mM Tris-HCl (pH 7.5), 150 mM NaCl and 10 mM CaCl 2 and incubated overnight at 4 °C. To purify MAD2 in the open conformation (O-MAD2), the labelling reaction was followed by ion-exchange chromatography (ResQ column, GE Healthcare) to remove the sortase A, excess TAMRA-conjugated peptide and MAD2 in the closed conformation (C-MAD2). FRET measurements. Fluorimeter scans were performed on a Fluoromax 4 (Jobin Yvon) in a buffer containing fresh 10 mM HEPES (pH 7.5), 150 mM NaCl, 2.5% glycerol, 10 mM β -mercaptoenthanol and 0.05% Triton X-100. Mixtures were excited at 430 nm and the emissions were scanned from 450 to 650 nm. Singlewavelength acceptor-fluorescence measurements were carried out at 583 nm. Mixtures of MAD1-C-MAD2 with BUB1-BUB3 and/or MPS1 were pre-incubated at 1 μ M for 30 min at 30 °C. Unless stated otherwise, assays were performed using 100 nM of all proteins (except CDC20, which was added at 500 nM). In all figure panels reporting time-dependent changes in FRET signal of MCC S1 and MCC S2 , curves report single measurements representative of at least three independent technical replicates. Kinetic analysis MCC catalysis. To determine the kinetic parameters for catalysis of MCC assembly, we measured initial rates of catalysis of 5 nM 'enzyme' (MAD1-MAD2, BUB1-BUB3 and MPS1, which were pre-activated by incubation at 1 μ M for 30 min at 30 °C with 1 mM ATP/MgCl 2 ) against 500 nM CDC20 and BUBR1, while the concentration of O-MAD2-TAMRA was varied. The initial rates of MCC assembly were calculated using a standard of fluorescence emission at 583 nm at known MCC concentrations. The initial rates were subsequently plotted against the concentration of MAD2, and subjected to nonlinear regression fitting using the Michaelis-Menten equation
, where V max is the maximal velocity at saturating substrate concentrations and K M is the Michaelis-Menten constant. The k cat value was derived from the equation
, where E 0 is the total enzyme concentration. Experimental data were processed using Prism 6 (Graphpad Software, Inc.). Fluorimeter scans were performed on a Fluoromax 4 (Jobin Yvon) in a buffer containing fresh 10 mM HEPES (pH 7.5), 150 mM NaCl, 2.5% glycerol, 10 mM β -mercaptoenthanol and 0.05% Triton X-100. Mixtures were excited at 430 nm and the emissions were measured at 583 nm.
MAD1-C-MAD2 and BUB1-BUB3 pull-down experiments. MBP-MAD1-C-MAD2
(1 μ M), BUB1-BUB3 (2 μ M), MPS1 (400 nM) and ATP (or variations thereof) were incubated for 1 h at room temperature in 1× kinase buffer (20 mM HEPES (pH 7.5), 50 mM NaCl, 10 mM MgCl 2 , 0.5 mM EGTA, 2 mM DTE, 0.01% Triton X-100). After incubation with equilibrated amylose beads for 30 min on ice (New England Biolabs), the beads were washed twice with 200 μ l wash buffer (50 mM HEPES (pH 7.5), 50 mM NaCl, 0.05% Triton, 10% glycerol, 2 mM DTE).
Following this, SDS loading buffer was added (to a final concentration of 62.5 mM Tris pH 6.8, 2% sodium dodecyl sulfate (SDS), 10% glycerol, 0.1 M DTT and 0.01% bromophenol blue), the sample boiled, and samples analysed by western blot. Mass spectrometry. Liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) was used to identify phosphorylation sites. Samples were digested with LysC/trypsin and/or GluC and prepared for LC-MS/MS analysis 38 . A total of 100 ng of peptides were separated on a Thermo Scientific EASY-nLC 1000 high-performance liquid chromatography system (Thermo Fisher Scientific, 1 h gradient from 5-60% acetonitrile with 0.1% formic acid) and directly sprayed using a nano-electrospray source in a quadrupole Orbitrap mass spectrometer (Q Exactive, Thermo Fisher Scientific) 39 . The Q Exactive was operated in datadependent mode acquiring one survey scan and subsequently ten MS/MS scans 40 . The resulting raw files were processed with MaxQuant software (version 1.5.2.18) using a reduced database containing only the proteins of interest and giving phosphorylation on serine, threonine and tyrosine as variable modification 41 . A false-discovery rate cut-off of 1% was applied at the peptide and protein levels and the phosphorylation site decoy fraction. Cell culture, plasmid transfection, microinjections, immunofluorescence, immunoblotting and imaging. HeLa cells or N-terminal localization and affinity purification peptide (LAP)-tagged LAP-BUB1 HeLa cells (MCB 2334; a gift from A. Hyman) were grown in DMEM (PAN Biotech) supplemented with 10% tetracycline-free FBS (PAN Biotech), l-glutamine (PAN Biotech) and either penicillin and streptomycin or G418 (GIBCO). Cells were grown at 37 °C in the presence of 5% CO 2 . CDK1 inhibition, microinjections and live imaging were performed in complemented CO 2 -independent medium (GIBCO) at 37 °C. For microinjections, a cDNA segment encoding human CENP-A was cloned in a pcDNA5/FRT/TO-IRES-mCherry vector, a modified version of pcDNA5/FRT/TO (Invitrogen) generated in-house as a C-terminal fusion to mCherry (M. Mattiuzzo and A. De Antoni). Transient transfections of pcDNA5/ FRT/TO-IRES-mCherry-CENPA were performed with Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions and the mCherry-CENPA fusion was expressed by addition of 200 ng/ml doxycycline (Sigma) for 48 h. Where indicated, nocodazole (Sigma) was used at 3.3 μ M and RO-3306 (Calbiochem) was used at 9 μ M for 18 h. Microinjections were performed using a combination of FemtoJet, InjectMan-NI2 and Femtotip-II, all purchased from Eppendorf. Recombinant CFP-BUBR1-BUB3 complex and TAMRA-MAD2 (or TAMRA) were injected at a concentration of 6 μ M and 2 μ M, respectively. The number of cells injected, n, was: for TAMRA, n = 2; for O-MAD2-TAMRA, n = 9; for CFP-BUBR1-BUB3, n = 8. Live-cell images were taken before injection and 1-10 min after injection.
The plasmid expressing mCherry-MIS12-MAD1 WT was a gift from T. Kapoor. The same plasmid background was used to transiently express a synthetically synthesized MAD1 gene harbouring the various alanine mutations. For this assay, HeLa cells growing on coverslips pre-coated with 15 μ g/ml poly-d-lysine (Millipore) were transiently transfected with the mCherry fusion plasmids using Lipofectamine 2000. Thirty hours after transfection, cells were either prepared for immunofluorescence or processed for western blotting analysis. Where indicated, cells were treated with 500 nM Reversine for 2 h before fixation. Cells were then fixed with PBS with 4% paraformaldehyde, followed by permeabilization with PBS/PHEM-Tween 0.3%. The following antibodies were used for immunostaining: anti-α -tubulin (mouse, DM1α , Sigma; 1:500), anti-CREST/anti-centromere antibodies (human, Antibodies Inc.; 1:100). DNA was stained with 0.5 μ g/ml DAPI (Serva) and coverslips mounted with Mowiol mounting medium (Calbiochem). For western blotting analysis the following antibodies were used: anti-α -tubulin (DM1α ; 1:10,000), anti-MAD1 (in-house-made mouse monoclonal, clone BB3-8/ e578-589; 1:100). Imaging for microinjection experiments was performed on a spinning disk confocal microscope of a 3i Marianas system (Intelligent Imaging Innovations) equipped with an Axio Observer Z1 microscope (Zeiss), a CSU-X1 confocal scanner unit (Yokogawa Electric Corporation), Plan-Apochromat 63× or 100× /1.4 NA objectives (Zeiss) and an Orca Flash 4.0 sCMOS Camera (Hamamatsu). Images were acquired as Z sections (using Slidebook Software 5.5 from Intelligent Imaging Innovations or using LCS 3D software from Leica) and converted into maximal-intensity-projection TIFF files for illustrative purposes. Imaging for the mCherry fusions experiments was performed on a Deltavision Elite System (GE Healthcare) equipped with an IX-71 inverted microscope (Olympus), a UPlanFLN 40× /1.3 NA objective (Olympus) and a pco.edge sCMOS camera (PCO-TECH Inc.). Images were acquired as Z sections (using the softWoRx software from Deltavision) and converted into maximal-intensity-projection TIFF files for illustrative purposes. Quantification of kinetochore signals was performed on unmodified Z series images using Imaris 7.3.4 software (Bitplane). Following background subtraction, a ratio for mCherry-MIS12-MAD1/CREST intensity signals was calculated. All ratios were normalized to the mean of letter reSeArCH mCherry-MIS12-MAD1
WT ratio. The HeLa cell line used in this study was regularly checked for mycoplasma contamination. The cell line was not authenticated. Data availability statement. All uncropped Coomassie-stained gels and western blots are provided in the Supplementary Information. All other data that support the findings of this study are available from the corresponding author upon request.
letter reSeArCH Monitoring the assembly of CDC20-MAD2 (MCC S1 ; blue), CDC20-MAD2 with dark BUBR1-BUB3 (MCC S1 ; red) and BUBR1-MAD2 with dark CDC20 (green) shows indistinguishable rates. e, Catalysis rates scale linearly with catalyst concentration. After preincubation of the catalyst proteins, MCC assembly was monitored with MCC S2 (sensor concentrations were 100 nM, except for CDC20, which was 500 nM) at varying catalyst concentrations. Initial velocity (V i ) signal changes were plotted against catalyst concentration, revealing a linear dependency. f, Catalysis of MCC formation could be observed with both FRET sensors. After pre-incubation of MAD1-C-MAD2, BUB1-BUB3 and MPS1 at 1 μ M for 30 min, similar catalysis rates were observed with either MCC S1 (blue) or MCC S2 (red). The assay was performed as described in Fig. 2b , with all proteins at 100 nM. Data are mean ± s.e.m. of three independent technical replicates of the experiments (b, e). Lowering both MAD1-C-MAD2 and BUB1-BUB3 (condition 5) mimics the reduction of all components (condition 8), whereas reducing MAD1-C-MAD2 or BUB1-BUB3 in combination with MPS1 (conditions 6 and 7, respectively) only resulted in intermediate rates. Assays were performed with MCC S2 as described in Fig. 2b , using either 100 nM (1× ) or 10 nM (0.1× ) catalysts. b, Excluding BUBR1 does not affect catalytic rates (green and blue). Assays were performed using MCC S1 , all proteins were present at 100 nM. c, The interaction between BUB1 and CDC20 enhances binding with MAD2. A BUB1 construct that does not bind CDC20 (the KEN1-ABBA mutant (BUB1 KEN1-ABBAmut ); purple) yields similar rates as in the absence of BUB1 (grey). Assay performed with MCC S2 and as described in Fig. 2b , using 100 nM catalysts. d, MAD1-C-MAD2 and BUB1-BUB3 show an ATP-dependent interaction in the presence of MPS1. Pull-down experiment using MBP-MAD1-C-MAD2 as bait. Assay was performed with 1 μ M MAD1-C-MAD2, 2 μ M BUB1-BUB3 and 400 nM MPS1. e, Values of FRET from MCC S2 (1 nM CFP-BUBR1 and 500 nM CDC20) after equilibration with or without catalysts (25 nM catalyst concentration). Data are mean ± s.e.m. of three independent technical replicates of the experiment (b, e).
